In First of Its Kind Legislation, Louisiana Cracks Down on White-Bagging Requirements

Louisiana has just enacted a law stopping insurers or their pharmacy benefit managers from requiring or pressuring in-network providers to accept "white bagging" of physician-administered drugs. | Shutterstock

Louisiana Gov. John Bel Edwards (D) has signed legislation stopping insurers or their pharmacy benefit managers from requiring or pressuring in-network providers to obtain physician-administered drugs exclusively from pharmacies in the insurer’s network.

SB 191, which took effect June

Read More »

More Than a Third of State Lawmakers Accept Pharma Campaign Contributions, Analysis Shows

More than one-third of all state lawmakers nationwide accepted at least one pharmaceutical industry campaign contribution during the past two years, an analysis of campaign finance records by news organization STAT found.

In the last two years, over one-third of all state lawmakers nationwide accepted at least one pharmaceutical industry campaign contribution, news organization STAT reports.

The industry wrote over 10,000 individual checks totaling more than $9 million to “at least 2,467

Read More »

Becerra’s Message to Pharma on 340B: “You Violate the Law, You Pay the Consequences”

HHS Secretary Xavier Becerra told a Senate committee this morning his department has sent drug companies "a clear message" that if they violate the 340B statute, they will "pay the consequences."

U.S. Health and Human Services (HHS) Secretary Xavier Becerra told a U.S. Senate Appropriations subcommittee this morning that his department has sent “a clear message” to six drug manufacturers denying 340B discounts on drugs shipped to contract pharmacies “that we

Read More »

Bristol Myers Squibb/Celgene Myeloma Drugs: Patient-Safety or Profit Motive? Part 4

Our six-part investigative series takes an in-depth look into a question often asked by 340B providers: Why can’t they access 340B pricing on one of Bristol Myers Squibb/Celgene’s most profitable drug products? We also delve into serious fraud allegations, Congressional oversight, and the possibility of a renewed focus on this contentious area under new leadership at the U.S. Health and Human Services Department. Throughout the series, we also provide BMS/Celgene's viewpoint, their justification for their drug pricing practices, limited distribution policies and why they believe they are following the law.

Part 4 of 6—How Do Celgene’s Revlimid Policies Affect 340B Hospitals and Patient Care?

The impact on health care providers of being unable to access Revlimid at the 340B price is significant, financially and in terms of patient care, according

Read More »

Bristol Myers Squibb/Celgene Myeloma Drugs: Patient-Safety or Profit Motive? Part 3

Our six-part investigative series takes an in-depth look into a question often asked by 340B providers: Why can’t they access 340B pricing on one of Bristol Myers Squibb/Celgene’s most profitable drug products? We also delve into serious fraud allegations, Congressional oversight, and the possibility of a renewed focus on this contentious area under new leadership at the U.S. Health and Human Services Department. Throughout the series, we also provide BMS/Celgene's viewpoint, their justification for their drug pricing practices, limited distribution policies and why they believe they are following the law.

Part 3 of 6—The Path From Thalidomide, to Revlimid, to a 340B Whistleblower Lawsuit

The myeloma drugs Revlimid and Pomalyst are analogues of Thalomid, aka thalidomide—a drug that still haunts those who remember the late 1950s and early 1960s. Marketed

Read More »

Bristol Myers Squibb/Celgene Myeloma Drugs: Patient-Safety or Profit Motive? Part 2

Our six-part investigative series takes an in-depth look into a question often asked by 340B providers: Why can’t they access 340B pricing on one of Bristol Myers Squibb/Celgene’s most profitable drug products? We also delve into serious fraud allegations, Congressional oversight, and the possibility of a renewed focus on this contentious area under new leadership at the U.S. Health and Human Services Department. Throughout the series, we also provide BMS/Celgene's viewpoint, their justification for their drug pricing practices, limited distribution policies and why they believe they are following the law.

Part 2 of 6—A Pharmaceutical Industry Insider’s Claims of Massive Fraud Against 340B Providers

Editor’s note: We invited Bristol Myers Squibb (BMS), which bought Celgene in November 2019, to respond to allegations of illegal or

Read More »

Bristol Myers Squibb/Celgene Myeloma Drugs: Patient-Safety or Profit Motive? Part 1

Our six-part investigative series takes an in-depth look into a question often asked by 340B providers: Why can’t they access 340B pricing on one of Bristol Myers Squibb/Celgene’s most profitable drug products? We also delve into serious fraud allegations, Congressional oversight, and the possibility of a renewed focus on this contentious area under new leadership at the U.S. Health and Human Services Department. Throughout the series, we also provide BMS/Celgene's viewpoint, their justification for their drug pricing practices, limited distribution policies and why they believe they are following the law.

Part 1 of 6—Why Can So Few 340B Hospitals Buy and Dispense the Highly Profitable Cancer Drug Revlimid?

Possibly more than a thousand hospitals in the 340B drug discount program can’t buy or dispense Revlimid, a widely-used oral drug

Read More »

Novartis Says Its Reputation Has Been Injured By HRSA’s 340B Demand Letter

Novartis said HRSA's demand letter is hindering its “ability to recruit talent and build relationships with the stakeholders necessary to develop pharmaceuticals that patients need.” | Shutterstock

Drug manufacturer Novartis told a judge last week that the government’s May 17 public statement that the company’s actions have resulted in overcharges and are in direct violation of the 340B statute has injured Novartis’ reputation among its customers and

Read More »

White House Clears Path for HRSA to Rescind Trump’s Health Center 340B Insulin Rule

The Biden administration moved a step closer yesterday to rescinding a Trump administration rule governing what 340B health centers can charge patients for insulin and epinephrine auto-injectors. | Shutterstock

The White House Office of Management and Budget (OMB) has completed its review of a key regulatory step toward rescinding the Trump administration’s final rule to require health centers to provide insulin and injectable epinephrine to low-income patients at the

Read More »

Health Centers Launch a New National Advocacy Group

Kerry Hydash (left) is Board Chair and Amanda Pears Kelly is Executive Director of the new health center group Advocates for Community Health.

Community health center leaders have created a new membership organization—Advocates for Community Health (ACH)—to influence federal health care policy and “drive a new vision for the role health centers can and should play in an evolving 21st century health care

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live